IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 228 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.35 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,929,819 | -3.7% | 274,122 | +31.0% | 0.01% | -12.5% |
| Q3 2022 | $2,004,000 | +23.3% | 209,187 | +42.1% | 0.01% | +33.3% |
| Q2 2022 | $1,625,000 | -40.1% | 147,227 | -9.6% | 0.01% | -33.3% |
| Q1 2022 | $2,713,000 | -4.7% | 162,939 | +9.2% | 0.01% | +12.5% |
| Q4 2021 | $2,847,000 | -10.8% | 149,157 | +15.3% | 0.01% | -20.0% |
| Q3 2021 | $3,190,000 | +33.0% | 129,378 | +40.3% | 0.01% | +25.0% |
| Q2 2021 | $2,399,000 | +9.7% | 92,188 | +33.4% | 0.01% | 0.0% |
| Q1 2021 | $2,187,000 | -34.0% | 69,083 | -3.3% | 0.01% | -33.3% |
| Q4 2020 | $3,316,000 | +29.9% | 71,464 | -7.8% | 0.01% | +20.0% |
| Q3 2020 | $2,553,000 | +35.3% | 77,538 | +12.8% | 0.01% | +25.0% |
| Q2 2020 | $1,887,000 | -37.3% | 68,746 | -31.6% | 0.01% | -46.7% |
| Q1 2020 | $3,011,000 | +8.2% | 100,571 | 0.0% | 0.02% | +50.0% |
| Q4 2019 | $2,784,000 | +59.0% | 100,571 | +4.5% | 0.01% | +42.9% |
| Q3 2019 | $1,751,000 | – | 96,200 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACUTA CAPITAL PARTNERS, LLC | 2,222,701 | $25,005,000 | 8.92% |
| Broadfin Capital, LLC | 4,894,361 | $55,062,000 | 8.10% |
| GREAT POINT PARTNERS LLC | 3,496,340 | $39,334,000 | 6.13% |
| FRAZIER MANAGEMENT LLC | 2,188,331 | $24,619,000 | 4.51% |
| Prosight Management, LP | 715,317 | $8,047,000 | 4.49% |
| Avoro Capital Advisors LLC | 8,662,720 | $97,456,000 | 4.48% |
| QVT Financial LP | 821,361 | $8,748,000 | 2.26% |
| Perceptive Advisors | 7,290,199 | $82,014,000 | 2.19% |
| Rhenman & Partners Asset Management AB | 1,290,495 | $14,518,000 | 1.46% |
| EMORY UNIVERSITY | 185,915 | $2,092,000 | 1.37% |